2023 Wisconsin Multiple Myeloma & Lymphoma Summit

Milwaukee, WI US
August 26, 2023

This CME-accredited activity, Wisconsin Multiple Myeloma & Lymphoma Summit, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia.

This activity aims to improve learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for induction and treatment for both transplant-eligible and transplant-ineligible with newly diagnosed multiple myeloma

  • Outline the management strategies for patients with 1-3 prior lines of therapy

  • Review indications and safety of CAR-T, bispecific antibodies MM, and lymphoma

  • Review the indications for the treatment of Waldenstrom Macroglobulinemia and current therapeutic strategies

  • Understand the evolving treatment strategies for the initial management of DLBCL

Hotel information

Hyatt Regency Milwaukee

A limited number of rooms have been reserved for the attendees of this conference at the Hyatt Regency Milwaukee at a discounted rate of $172 per night. Reserve your room at the following link by July 28th, 2023, to receive the discounted rate: https://www.hyatt.com/en-US/group-booking/MKERM/G-MYEL
 
 
 

GOLD SPONSOR

Course summary
Available credit: 
  • 5.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.00 Contact Hours.
Course opens: 
03/10/2023
Course expires: 
11/27/2023
Event starts: 
08/26/2023 - 8:00am PDT
Event ends: 
08/26/2023 - 1:45pm PDT
Cost:
$350.00
Add to calendar: 

Conference Chair: Binod Dhakal, MD, MS

Aug 26, 2023

All times below are listed in Central Time (CT). 
 

07:00 AM - 08:00 AM: BREAKFAST, REGISTRATION, & EXHIBITS

08:00 AM - 08:05 AM: Welcome & Opening Remarks - Binod Dhakal, MD, MS

08:05 AM - 08:15 AM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD

08:15 AM - 09:15 AM: SESSION 1 - APPROACH TO NEWLY DIAGNOSED MULTIPLE MYELOMA

Session Chair: Binod Dhakal, MD, MS

08:15 AM - 08:35 AM: The Evolving Paradigm of Induction Therapy in Transplant-Eligible Patients - Marcelo Pasquini, MD

08:35 AM - 08:55 AM: Transplant Ineligible Myeloma Patients: Is Proteasome Inhibitor Necessary? - Timothy Schmidt, MD

08:55 AM - 09:15 AM: Panel Discussion - Marcelo Pasquini, MD & Timothy Schmidt, MD

09:15 AM - 10:15 AM: SESSION 2 - RELAPSED AND REFRACTORY MYELOMA AND EMERGING THERAPIES

Session Chair: Marcelo Pasquini, MD

09:15 AM - 09:35 AM: Treatment Options in Patients with Early Relapse in MM - Ravi Narra, MD, MS

09:35 AM - 09:55 AM: How to Choose and Sequence CAR-T vs Bispecific Antibodies in MM - Meera Mohan, MD, MS, FACP

09.55 AM - 10:15 AM: Panel Discussion - Ravi Narra, MD, MS & Meera Mohan, MD, MS, FACP

10:15 AM - 10:40 AM: BREAK & EXHIBITS

Product Theater Sponsored by Sanofi - in breakout room Executive / Milwaukee

Title:   SARCLISA + Kd: An Anti-CD38 Combination for the Treatment of Multiple Myeloma Patients as Early as First Relapse

Presenter:  William Bensinger, MD, Center for Blood Disorders and Stem Cell Transplant, Swedish Tumor Institute, Seattle, Washington 

10:40 AM - 11:40 AM: SESSION 3 - MANAGEMENT OF INDOLENT LYMPHOMAS

Session Chair: Sanjal Desai, MD

10:40 AM - 11:00 AM: Treatment Update in Mantle Cell Lymphoma - Timothy Fenske, MD, MS

11:00 AM - 11:20 AM: Targeted Agents and Immunotherapy in Follicular Lymphoma - Parameswaran Venugopal, MD

11:20 AM - 11:40 AM: Panel Discussion - Timothy Fenske, MD, MS & Parameswaran Venugopal, MD

11:40 AM - 12:40 PM: LUNCH & EXHIBITS

Product Theater Sponsored by Janssen - in breakout room Executive / Milwaukee

Title:  A Treatment for Adult Patients with RRMM who have Received at Least Four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody

Presenter: Hanna Safah

12:40 PM - 01:40 PM: SESSION 4 -  MANAGEMENT OF AGGRESSIVE LYMPHOMAS

Session Chair: Parameswaran Venugopal, MD

12:40 PM - 01:00 PM: Frontline Treatment of Patients with DLBCL - Sumana Devata, MD

01:00 PM - 01:20 PM: CAR-T and Bispecific Antibodies in DLBCL - Sanjal Desai, MD

01:20 PM - 01:40 PM: Panel Discussion - Sumana Devata, MD & Sanjal Desai, MD

1:40 PM - 02:40 PM: TUMOR-BOARD STYLE CASE-BASED PRESENTATIONS                                                                                       

Session Chairs: Binod Dhakal, MD, MS & Paul Rubinstein, MD

1:40 PM - 1:50 PM: Relapsed/refractory multiple myeloma - Jennifer Obasi, MD

1:50 PM - 2:00 PM: Secondary pure red cell aplasia secondary to multiple myeloma - Jennifer Obasi, MD

2:00 PM - 2:10 PM: Management of High-Risk Multiple Myeloma in Era of Quadruple Therapy - Gulrayz Ahmed, MD, FACP

2:10 PM - 2:20 PM: Treatment for Relapsed DLBCL Beyond Autologous Transplant and Car-T -  Gulrayz Ahmed, MD, FACP

2:20 PM - 2:30 PM: Aggressive Lymphoma: Management of Unique Cases - Amer Al Homssi, MD

2:30 PM - 2:40 PM: Panel Discussion

02:40 PM: Adjourn      

Hyatt Regency Milwaukee
333 W Kilbourn Ave
Milwaukee, WI 53203
United States
+1 (414) 270-6035
Binaytara Foundation Reservation Link

A limited number of rooms have been reserved for the attendees of this conference at the Hyatt Regency Milwaukee at a discounted rate of $172/night. Reserve your room at the following link by July 28th, 2023, to receive the discounted rate: https://www.hyatt.com/en-US/group-booking/MKERM/G-MYEL

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Binod Dhakal, MD, MS

has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with GSK;.
has a financial relationship (Other) with Natera;.
has a financial relationship (Other) with Celgene/BMS;.
has a financial relationship (Other) with Sanofi;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Moderator(s)

Paul Rubinstein

has no relevant financial relationships to disclose at this time.
Planner(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker(s)

Gulrayz Ahmed, MD, FACP

has no relevant financial relationships to disclose at this time.

Amer Al Homssi, MD

has no relevant financial relationships to disclose at this time.

Sanjal Desai, MD

has a financial relationship (Other) with Seagen;.

Sumana Devata, MD

has a financial relationship (Stock) with Astra Zeneca;.
has a financial relationship (Stock) with Bristol Myers Squibb;.
has a financial relationship (Stock) with GSK;.
has a financial relationship (Stock) with Pfizer;.
has a financial relationship (Stock) with Abbvie;.
has a financial relationship (Stock) with Eli Lilly;.
has a financial relationship (Stock) with Novo Nordisk;.
has a financial relationship (Stock) with Johnson &Johnson;.
has a financial relationship (Stock) with Bayer;.
has a financial relationship (Stock) with Merck;.

Timothy Fenske

has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Independent contractor) with Astrazeneca;.
has a financial relationship (Independent contractor) with MorphoSys;.
has a financial relationship (Independent contractor) with Adaptive Biotechnologies;.
has a financial relationship (Independent contractor) with Lilly/Loxo;.
has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Kite (Gilead);.
has a financial relationship (Independent contractor) with Sanofi;.

Meera Mohan, MD, MS

has no relevant financial relationships to disclose at this time.

Ravi Kishore Narra, MD.,MS

has no relevant financial relationships to disclose at this time.

Jennifer Obasi

has no relevant financial relationships to disclose at this time.

Marcelo Pasquini, MD, MS

has a financial relationship (Grant Or Contract) with Gilead Brazil;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Janssen ;.
has a financial relationship (Grant Or Contract) with Kite Pharma;.

Timothy Schmidt, MD

has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Janssen;.

Parameswaran Venugopal, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 5.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $350

Non-physician HCP (non-industry) - $250

Industry representatives - $850

Fellow or resident - $0

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.